alterations,drugs,approvedIndications,level,fdaLevel,levelAssociatedCancerType,levelExcludedCancerTypes,pmids,abstracts,description
['D1228N'],"[{'ncitCode': 'C74061', 'drugName': 'Crizotinib'}]",[],LEVEL_R2,LEVEL_Fda3,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],"['27343442', '28396313', '27987579', '29128427', '28522754']",[],"Capmatinib, crizotinib and cabozantinib are small-molecule inhibitors of MET that are FDA-approved and/or NCCN-listed for adult patients with metastatic non-small cell lung cancer (NSCLC) harboring MET alterations. Across multiple studies of patients with NSCLC who were treated with MET inhibitors, the MET D1228N mutation was found in five patients with acquired resistance to crizotinib, one patient with acquired resistance to cabozantinib and one patient with acquired resistance to capmatinib (PMID: 27343442, 29128427, 28522754, 28396313, 27987579)."
['D1228N'],"[{'ncitCode': 'C52200', 'drugName': 'Cabozantinib'}]",[],LEVEL_R2,LEVEL_Fda3,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],"['27343442', '28396313', '27987579', '29128427', '28522754']",[],"Capmatinib, crizotinib and cabozantinib are small-molecule inhibitors of MET that are FDA-approved and/or NCCN-listed for adult patients with metastatic non-small cell lung cancer (NSCLC) harboring MET alterations. Across multiple studies of patients with NSCLC who were treated with MET inhibitors, the MET D1228N mutation was found in five patients with acquired resistance to crizotinib, one patient with acquired resistance to cabozantinib and one patient with acquired resistance to capmatinib (PMID: 27343442, 29128427, 28522754, 28396313, 27987579)."
['D1228N'],"[{'ncitCode': 'C90564', 'drugName': 'Capmatinib'}]",[],LEVEL_R2,LEVEL_Fda3,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],"['27343442', '28396313', '27987579', '29128427', '28522754']",[],"Capmatinib, crizotinib and cabozantinib are small-molecule inhibitors of MET that are FDA-approved and/or NCCN-listed for adult patients with metastatic non-small cell lung cancer (NSCLC) harboring MET alterations. Across multiple studies of patients with NSCLC who were treated with MET inhibitors, the MET D1228N mutation was found in five patients with acquired resistance to crizotinib, one patient with acquired resistance to cabozantinib and one patient with acquired resistance to capmatinib (PMID: 27343442, 29128427, 28522754, 28396313, 27987579)."
